Target intelligence / Profile preview

Non-Helicobacter pylori Helicobacter (NHPH)

Target
NHPH
Molecular classification
Gram-negative bacteria, Pathogen, Urease-producing organism
01

Overview

Non-Helicobacter pylori Helicobacter (NHPH) refers to a group of spiral-shaped, Gram-negative, urease-positive bacteria that colonize the gastric mucosa of humans and animals. While Helicobacter pylori is the most common gastric pathogen, NHPH species such as H. heilmannii, H. suis, and H. felis are increasingly recognized as significant causes of gastric pathology, including chronic gastritis and MALT lymphoma (Source: PMID: 29403380). These organisms utilize the enzyme urease to neutralize gastric acid by producing ammonia, allowing them to survive in the harsh acidic environment of the stomach. Clinical management typically mirrors H. pylori eradication protocols, utilizing a combination of proton pump inhibitors and broad-spectrum antibiotics. However, NHPH infections are often underdiagnosed due to their fastidious growth requirements and the limitations of standard diagnostic tests, frequently requiring molecular methods like PCR for definitive identification (Source: PMID: 31643458).

Other names
Non-pylori Helicobacter speciesGastric NHPHHelicobacter heilmannii sensu latoUrease-positive non-pylori gastric bacteria
02

Mechanism of action

Therapeutic strategies involve the use of multi-drug regimens including proton pump inhibitors to increase gastric pH and antibiotics to inhibit bacterial cell wall synthesis (beta-lactams), protein synthesis (macrolides/tetracyclines), or DNA replication (fluoroquinolones/nitroimidazoles) (Source: PMID: 33114340).

03

Biological functions

Urease productionGastric mucosal colonizationAmmonia productionInduction of inflammatory cytokinesEvasion of host immune response
04

Disease associations

Chronic gastritisPeptic ulcer diseaseGastric MALT lymphomaGastric adenocarcinomaDyspepsia
05

Safety considerations

Antibiotic resistance developmentDisruption of commensal gut microbiotaAdverse gastrointestinal effects from triple therapyPotential for zoonotic transmission
06

Interacting drugs

Amoxicillin

7 more in the full profile.

07

Biomarkers

Urea breath test (UBT)Rapid urease test (RUT)16S rRNA PCR sequencingGastric biopsy histologyWarthin-Starry silver stain

Beyond the preview

Go deeper on Non-Helicobacter pylori Helicobacter (NHPH).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Non-Helicobacter pylori Helicobacter (NHPH).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call